Resources

Categories
  1. Lower prices negotiated on 16 medicines

    Lower prices negotiated and provided as part of our ongoing mission to make medicines more accessible. 
    new prices 

    Read more »
  2. 2018 - Good year for new FDA approvals of cancer treatments

    2018 has been a good year for new cancer treatments says the U.S. AACR. 
    AACR news 

    Read more »
  3. Kisqali (ribociclib) approved for additional indications in HR+/HER2- advanced breast cancer

    News updateKisqali is now the only CDK4/6 inhibitor for use with an aromatase inhibitor for the treatment of pre-, peri- or postmenopausal women in the US.

    Read more »
  4. In-depth review of the new EMA-approved preventative migraine injection

    The approval marks a significant advance in the field of neurology — and one that migraine patients will no doubt welcome.

    News update


    Read more »
  5. Erenumab (Aimovig) now approved for the European Union

    The new preventive medicine for migraine Aimovig (erenumab) has been approved by the EMA. Read more...
    Breaking News 

    Read more »
  6. 10 important facts to know about the new migraine injection

    You might have heard about a new medicine that’s just been approved to treat migraine. Here’s what you need to know.

    Glasses

    Read more »
  7. A new answer for treating migraines?

    7 need-to-knows about migraine as well as some updates on the latest treatment developments

    Blog post

    Read more »
  8. FDA grants accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for metastatic colorectal cancer

    Industry News

    Read more »
  9. Array BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations

    Industry News

    Read more »
  10. What is ‘cold chain’ delivery?

    Find out about what it means to order and receive temperature-controlled medicines.

    Map

    Read more »
  11. Image of the Year shows exceptional responses to cancer treatment

    Industry NewsThe dramatic before-and-after images show eight men's incredible response to cutting-edge treatment. 

    Read more »
  12. What’s after platinum-based chemo?

    Dandelion (conceptual)A closer look at the function and efficicacy of niraparib as a maintenace treatment.

    Read more »
  13. New immunotherapy shows reduction in tumor size for NSCLC patients

    Industry NewsIt’s believed that this immunotherapy and its dual approach to fighting cancer will be a notable complement to existing immuno-oncology treatments.

    Read more »
  14. Response to Keytruda (pembrolizumab) better in older patients, study suggests

    Industry NewsResearchers believe these differences are due to a reduced immunosuppressive tumor environment in older patients.

    Read more »
  15. Full marketing authorisation for blinatumomab

    Industry NewsThe latest approval renders the previous 'temporary approval' a full approval, without further results needed.

    Read more »
  16. T-cell therapy yields objective response rate of 52% in lymphoma (DLBCL) patients

    Industry NewsThe 52% (95% CI, 41-62) ORR included a complete response rate of 40% and a partial response rate of 12%.

    Read more »
  17. A wearable device for opioid withdrawal?

    Industry NewsThe FDA has approved a wearable device to treat withdrawal symptoms such as agitation, anxiety, depression, and opiate cravings.

    Read more »
  18. Keytruda-chemo combination shows beneficial response in treating metastatic NSCLC

    Industry NewsResearchers say the addition of Keytruda (pembrolizumab) in this study almost doubled the response rate of chemo for patients with NSCLC.

    Read more »
  19. New study suggests men and women may benefit differently from some immunotherapy medications

    News updateThe study showed that the relative survival gain almost doubled in men, compared to female patients, regardless of the type of cancer and drugs given.

    Read more »
  20. Looking inside and looking ahead: TheSocialMedwork quarter in review

    TSM TeamOur quarterly review was an opportunity to take stock and support an organisation fuelled by a mission aligned to ours: to make the lives of other human beings better.

    Read more »
  21. An interview with Ying Feng, Pharmacist and Support Team Member

    "My role is to guide a patient or their loved ones (sometimes that’s a partner, but it could also be a friend, relative or a doctor) through the process of what we do for them."

     Ying - Support Manager

    Read more »
  22. PRESS RELEASE: Brits with ALS, MS and cancer need not wait years

    UK Press Release

    Read more »
  23. PRESSEMITTEILUNG: Krebs kennt kein Vaterland - launch von TheSocialMedwork.com in Deutschland

    German Press Release

    Read more »
  24. PRESS RELEASE: New Hope for Australian sufferers of Ovarian Cancer and Soft Tissue Sarcoma

    Australian Press Release

    Read more »
  25. PRESS RELEASE: FDA approved medicines could help save Australian lives

    Australian Press Release

    Read more »
  26. Keytruda (pembrolizumab) given accelerated approval for cervical cancer

    industry news

    Read more »
  27. Tagrisso gets the green light for first-line lung cancer treatment in Europe

    Industry NewsTagrisso (osimertinib) has been approved in Europe to treat Epidermal Growth Factor Receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as a first-line treatment. 

    Read more »
  28. All about erenumab (Aimovig): the unique new migraine treatment

    A new preventive migraine treatment, Aimovig (erenumab-aooe), poses promising possibilities for some migraine sufferers.

    Aimovig

    Read more »
  29. Imfinzi may offer patients benefits in earlier stages of lung cancer

    Industry NewsNew clinical results show that Durvalumab improved survival (versus a placebo) in patients with non–small cell lung cancer.

    Read more »
  30. New relief for migraine patients?

    News updateThe first-ever preventative treatment for migraine in adults, Aimovig (erenumab-aooe) is now approved by the Food and Drug Administration.

    Read more »
CA